PodParley PodParley
PodParley
Program Director's Choice from SABCS2025 - Part 2: Sacituzumab Govitecan for Endocrine Therapy-refractory Advanced Breast Cancers episode artwork

EPISODE · Jan 21, 2026 · 7 MIN

Program Director's Choice from SABCS2025 - Part 2: Sacituzumab Govitecan for Endocrine Therapy-refractory Advanced Breast Cancers

from Medical Digest & Congress Report · host Medical Congress News

Kate Lathrop, MD discuss one of the high impact, clinically relevant, clinical trial, the ASCENT-07 trial that were presented at the San Antonio Breast Cancer Symposium 2025.Video: https://medicaldigest.org/scientific-contents/interview:program-directors-choice-sabcs2025-part-2-sacituzumab-govitecan-endocrine-therapy-refractory-advanced-breast-cancers

Episode metadata supplied by the publisher feed · Published Jan 21, 2026

Embed this episode

NOW PLAYING

Program Director's Choice from SABCS2025 - Part 2: Sacituzumab Govitecan for Endocrine Therapy-refractory Advanced Breast Cancers

0:00 7:43

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Medical Digest & Congress Report?

This episode is 7 minutes long.

When was this Medical Digest & Congress Report episode published?

This episode was published on January 21, 2026.

Can I download this Medical Digest & Congress Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!